OncoMatch/Clinical Trials/NCT05757219
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
Is NCT05757219 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Chimeric antigen receptor (CAR) T-cell therapy and Itacitinib for diffuse large b cell lymphoma.
Treatment: Itacitinib · Chimeric antigen receptor (CAR) T-cell therapy — The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Prior treatment with chimeric antigen receptor (CAR) T-cell therapy
Cannot have received: investigational agent
currently receiving or who have received any investigational study agent ≤4 weeks prior to screening visit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05757219 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify